COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients

Letter Dermatology

Rituximab: a safe therapeutic option during the COVID-19 pandemic?

Ambra Di Altobrando et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Add to Collection

Letter Dermatology

COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases

Michael Kasperkiewicz

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?

Tugba Kevser Uzuncakmak et al.

Summary: The study found that pemphigus patients who have received rituximab treatment within the previous 5 years have a lower risk of COVID-19 infection, regardless of the number of treatment courses or the duration since treatment. The disease course was mild in the only infected patient, suggesting that rituximab may be used for pemphigus treatment during the COVID-19 pandemic if necessary.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Letter Dermatology

Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study

Hamidreza Mahmoudi et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Letter Dermatology

Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

M. Kasperkiewicz et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Dermatology

The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study

Khalaf Kridin et al.

Summary: The study found that patients with bullous pemphigoid have an increased risk of COVID-19-associated mortality, while patients with pemphigus have similar risks as their controls. The use of systemic corticosteroids and immunosuppressants did not predispose patients to more severe illness from COVID-19.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Immunology

Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab

Jo Linda Sinagra et al.

Summary: Managing patients with chronic autoimmune diseases during the COVID-19 pandemic is challenging due to the risks associated with the conditions themselves and drug-induced immunosuppression. In the case of pemphigus patients, immunosuppressant therapies like rituximab can pose a risk of increased susceptibility to infections, despite being highly effective treatments.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Letter Dermatology